Tumor-targeting pharmaceutical combinations
AssigneesYeda Research and Development Co. Ltd., Baccine Ltd.
InventorsRavid STRAUSSMAN, Oded SANDLER, Deborah Gitta ROSENBERG
Life of this patent
Estimating the term…
Abstract
A pharmaceutical combination and uses thereof, wherein the pharmaceutical combination comprises a tumor-homing bacteria and a host-transient bacterial adjuvant comprising a supplementary dose of an immunostimulant.
Claims30
A pharmaceutical combination comprising:
- (a) a dose of tumor-homing bacteria that is at least 50% less than the tumor-homing bacteria's maximum tolerated dose (MTD);
- and
- (b) a host-transient bacterial adjuvant comprising a supplementary dose of an immunostimulant, or a derivative or precursor thereof.
A pharmaceutical combination comprising one or more physiologically acceptable carriers and two bacterial strains:
- (a) an immunoactive-transient-bacteria genetically modified for transient survival in human serum, inducible synthesis of an immunostimulant, or transient synthesis of an immunostimulant;
- and
- (b) a tumor-homing bacteria which is an immunoactive-constitutive-bacteria.
A method of modulating an immune system response and enhancing tumor-homing, comprising administering to a host circulatory system a tumor-homing bacteria constitutively expressing an immunostimulant, or a derivative or precursor thereof;
- and
- a host-transient bacterial adjuvant comprising a supplementary dose of an immunostimulant, or a derivative or precursor thereof.
A method of preventing, delaying the progression of, or treating a cancer, comprising administering to a host circulatory system a tumor-homing bacteria constitutively expressing an immunostimulant, or a derivative or precursor thereof;
- and
- a host-transient bacterial adjuvant comprising a supplementary dose of an immunostimulant, or a derivative or precursor thereof.
Dependencies are inferred from the claim text.